相关实验视频
Updated: Jul 6, 2025

08:49
Murine Ileocolic Bowel Resection with Primary Anastomosis
Published on: October 29, 2014
16.5K
内镜治疗与性结肠炎患者生物治疗失败的风险降低有关
Akira Komatsu1, Takahiko Toyonaga2, Natsuki Sumiyoshi1
1Department of Gastroenterology and Hepatology, The Jikei University School of Medicine, Tokyo, Japan.
Scientific reports
|January 3, 2024
概括
用生物药物治疗的性结肠炎 (UC) 患者的内镜治疗与持续的治疗成功有关. 实现内镜治疗显著降低了由于反应丧失而导致生物治疗失败的风险.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 生物疗法越来越多地用于性结肠炎 (UC).
- 内镜治疗 (EH) 与UC中生物治疗失败之间的关系尚不清楚.
- 失去反应 (LOR) 是停止生物治疗的常见原因.
研究的目的:
- 研究内镜治疗 (EH) 与UC患者生物治疗失败的风险之间的关联.
- 为了确定EH是否预测了对生物治疗的持续反应.
- 分析EH对药物持续率和LOR的影响.
主要方法:
- 从UC患者开始生物治疗的医学数据的回顾性收集.
- EH的定义是梅奥内镜子分值为0或1.
- 使用卡普兰-梅尔估计器和考克斯回归分析对LOR-free药物持续率的比较.
主要成果:
- 在52名患者中,33名患者在2年内实现了EH;所有人都在没有LOR的情况下继续治疗.
- 20名患者没有达到EH,其中8人因LOR而停止治疗.
- 获得EH的患者的药物持续率显着更高 (p < 0.001).
- 脑膜炎是一个独立的因素,降低了与LOR相关的生物治疗失败的风险 (HR = 0.0324,p < 0.001).
结论:
- 2年内内镜治疗与UC中LOR相关的生物治疗失败的风险降低密切相关.
- 达到EH是UC中生物药物长期治疗成功的重要预测因素.
- 在生物治疗UC患者的管理中,EH应该是关键的目标.
相关概念视频
Inflammatory Bowel Disease V: Surgical Management
147
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
147
Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128
Drugs for Treatment of Ulcerative Colitis in IBD
144
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
144
Inflammatory Bowel Disease I: Ulcerative Colitis
187
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
187
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
140
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
140
Chronic Bowel Disorders: Introduction
455
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
455

